Bristol down as Street reacts to admilparant results in IPF

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for admilparant in treating idiopathic pulmonary fibrosis, showing significant lung function improvement at 60 mg. The company offers a 4.3% dividend yield, a 41% payout ratio, and a GF Score of 72, indicating strong fundamentals. BMY's stock is near a 5-year low P/E of 12.57x, suggesting potential value. Insider activity shows net selling, while guru ownership is mixed.

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for RYZ101, an investigational radiopharmaceutical therapy. The study met its primary endpoint, showing a significant improvement in progression-free survival for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company plans to discuss next steps with the FDA. BMY shares are currently trading at $57.25, down 3.21%.

Bristol Myers Squibb reported that its experimental lung disease drug admilparant showed mixed results in a Phase 3 trial, with only the 60 mg dose significantly slowing breathing decline in idiopathic pulmonary fibrosis patients. The 120 mg dose did not meet statistical significance, raising questions. The company stated the drug had a well-tolerated safety profile. Analysts and investors had concerns due to prior trial revisions and liver safety issues.

Bristol Myers Squibb (BMY) shares rose after positive Phase 3 results for RYZ101 and admilparant. RYZ101 showed improved progression-free survival in neuroendocrine tumors, while admilparant met primary endpoints in lung function decline. Both drugs face regulatory and market uncertainties. BMY aims to offset declining revenue with these innovations, but financial impact depends on approvals and adoption.

Bristol Myers Squibb reported that its experimental cancer therapy, RYZ101, significantly delayed disease progression in patients with rare, advanced gastrointestinal and pancreatic tumors. The company acquired the therapy through its $4.1 billion takeover of RayzeBio. Shares of Bristol Myers rose nearly 2%. The late-stage trial tested RYZ101 against standard treatments in patients with gastroenteropancreatic neuroendocrine tumors.

Bristol Myers Squibb reported that its experimental radiopharmaceutical therapy, RYZ101, slowed disease progression in patients with rare, advanced gastrointestinal and pancreatic tumors. The company acquired RYZ101 through its $4.1 billion takeover of RayzeBio. Shares rose nearly 4% premarket. The late-stage trial tested RYZ101 against standard treatments in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).